Zanubrutinib Better Than Ibrutinib in CLL/SLL? Zanubrutinib Better Than Ibrutinib in CLL/SLL?

An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news